Welcome to our dedicated page for Arcus Bioscience news (Ticker: RCUS), a resource for investors and traders seeking the latest updates and insights on Arcus Bioscience stock.
Arcus Biosciences, Inc. (NYSE: RCUS) generates frequent news as a clinical-stage, global biopharmaceutical company advancing investigational therapies for cancer, inflammatory diseases and autoimmune diseases. News about Arcus often centers on clinical trial updates for its lead programs, collaboration developments and corporate financing activities that support its pipeline.
Key oncology news items include data readouts and study milestones for casdatifan, a small-molecule HIF‑2α inhibitor being developed for clear cell renal cell carcinoma (ccRCC). Investors can follow announcements from the ARC‑20 Phase 1/1b study in late-line and early-line ccRCC, the global Phase 3 PEAK‑1 trial in immunotherapy-experienced metastatic ccRCC, and the eVOLVE‑RCC02 Phase 1b/3 study that combines casdatifan with volrustomig in first-line metastatic ccRCC. Updates often highlight progression-free survival, response rates, safety findings and the design of new cohorts or registrational strategies.
Arcus news also covers its broader oncology portfolio, including quemliclustat, a CD73 inhibitor in the PRISM‑1 Phase 3 trial for first-line metastatic pancreatic ductal adenocarcinoma, and the domvanalimab plus zimberelimab combinations in gastrointestinal and lung cancers. Coverage has included positive survival and response data from the Phase 2 EDGE‑Gastric study, as well as the later decision to discontinue the Phase 3 STAR‑221 and EDGE‑Gastric studies after an interim analysis showed no overall survival benefit over standard therapy.
On the inflammation and immunology side, Arcus issues updates on its emerging small-molecule programs targeting MRGPRX2, TNF, CCR6 and CD40L, and an anti‑CD89 antibody program. News may describe preclinical progress, selection of development candidates and plans to enter the clinic in indications such as atopic dermatitis, chronic spontaneous urticaria, rheumatoid arthritis, psoriasis, inflammatory bowel disease, multiple sclerosis and systemic lupus erythematosus.
Corporate and financial news for RCUS includes public equity offerings, amendments to loan facilities, participation in major healthcare and investor conferences, and guidance on cash runway. Readers can use this news page to follow how clinical data, partnership decisions with Gilead Sciences and Taiho Pharmaceutical, and capital-raising activities shape Arcus’s development priorities over time.
Arcus Biosciences (NYSE:RCUS) has granted stock options to eight new employees, totaling 66,400 shares at an exercise price of $31.48 per share, reflecting the closing price on October 8, 2021. This grant was made under the Company's 2020 Inducement Plan, approved in January 2020. Arcus is focused on developing cancer therapies, with five molecules currently in clinical trials, including Etrumadenant and Quemliclustat, addressing various cancer types. The company aims to meet significant unmet medical needs in oncology.
Arcus Biosciences (NYSE:RCUS) announced the granting of stock options to eight new employees, allowing them to purchase a total of 58,200 shares at $36.99 each, the closing price on September 23, 2021. This action is part of the 2020 Inducement Plan approved by the Board. The company is focused on oncology and has five clinical molecules in development, including Etrumadenant, Quemliclustat, and Domvanalimab, targeting various cancers with innovative therapies.
Arcus Biosciences, Inc. (NYSE: RCUS) has granted five new employees options to purchase a total of 44,200 shares at an exercise price of $34.31, reflecting the closing price on September 8, 2021. This grant is part of the Company's 2020 Inducement Plan, approved by the Board in January 2020, in compliance with NYSE regulations. Arcus focuses on developing innovative cancer therapies, with five molecules currently in clinical development addressing significant unmet medical needs.
Arcus Biosciences (NYSE:RCUS) announced its upcoming presentations at two virtual investor conferences in September 2021. The Citi’s 16th Annual Virtual Biopharma Conference will take place on September 10 at 1:25 pm ET, followed by the 2021 Cantor Virtual Global Healthcare Conference on September 27 at 4:40 pm ET. Investors can access a live audio webcast through the company’s website, with a replay available for two weeks post-event. Arcus focuses on developing innovative cancer therapies, currently advancing five molecules in clinical trials.
Arcus Biosciences (NYSE:RCUS) has granted stock options for 104,200 shares to twelve new employees at an exercise price of $29.35, reflecting the closing price on August 23, 2021. This grant is part of the 2020 Inducement Plan approved in January 2020, under NYSE Manual Rule 303A.08. The company is dedicated to developing innovative cancer therapies and currently has five drugs in clinical development, including Etrumadenant and Quemliclustat, targeting various cancer types.
Arcus Biosciences (NYSE:RCUS) announced that its Compensation Committee granted stock options for 30,400 shares to four new employees. The options are priced at $28.24 per share, equivalent to the closing price on August 9, 2021. This issuance falls under the Company’s 2020 Inducement Plan, approved in January 2020. Arcus Biosciences focuses on developing innovative cancer therapies, with five molecules currently in clinical development targeting various oncology indications.
Arcus Biosciences (NYSE:RCUS) reported its Q2 2021 financial results, showing significant advancements in its oncology portfolio. The company ended June with cash and investments of $805.1 million, an increase from $735.1 million in December 2020, primarily due to a $220.4 million stock placement with Gilead. Collaboration revenues surged to $9.5 million, compared to $1.8 million a year earlier. However, the net loss rose to $76 million in Q2 2021, up from $45.1 million in Q2 2020, indicating increased operational costs.
Arcus Biosciences, Inc. (NYSE:RCUS), a biopharmaceutical company focused on oncology, will present at the 2021 Wedbush PacGrow Virtual Healthcare Conference on August 11, 2021, at 1:45 p.m. ET. The presentation will be accessible via a live audio webcast on the company's website, with a replay available for two weeks post-event. Arcus is advancing five clinical molecules, including Etrumadenant (AB928) and AB680, targeting multiple cancers. The company's innovative approaches aim to address significant unmet medical needs in cancer therapy.
Arcus Biosciences (NYSE:RCUS) will report its financial results for Q2 2021 on August 5, 2021, after market close. A conference call to discuss these results and corporate highlights will begin at 1:30 PM PT/4:30 PM ET. Investors can join via phone or listen to a live webcast on the company's website. Arcus is advancing five molecules in clinical development, including Etrumadenant and AB680, targeting various cancers with promising therapies aimed at addressing unmet medical needs.
Arcus Biosciences (NYSE:RCUS) announced the grant of stock options for 72,800 shares to six new employees at an exercise price of $32.85, corresponding to the closing price on July 23, 2021. This grant is made under the Company’s 2020 Inducement Plan, approved by its Board of Directors. Arcus focuses on developing innovative cancer therapies and has five molecules in clinical development, including Etrumadenant and Domvanalimab, targeting significant unmet needs in various cancers. The company aims to advance its portfolio through clinical trials and collaborations.
FAQ
What is the current stock price of Arcus Bioscience (RCUS)?
What is the market cap of Arcus Bioscience (RCUS)?
